Atherosclerosis
Volume 211, Issue 1 , Pages 224-230 , July 2010

ADAM33 expression in atherosclerotic lesions and relationship of ADAM33 gene variation with atherosclerosis

  • John W. Holloway

      Affiliations

    • Human Genetics, School of Medicine, University of Southampton, Southampton, UK
    • Infection, Inflammation & Immunity, School of Medicine, University of Southampton, Southampton, UK
    • ,
  • Ross C. Laxton

      Affiliations

    • Human Genetics, School of Medicine, University of Southampton, Southampton, UK
    • Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    • ,
  • Matthew J. Rose-Zerilli

      Affiliations

    • Human Genetics, School of Medicine, University of Southampton, Southampton, UK
    • Infection, Inflammation & Immunity, School of Medicine, University of Southampton, Southampton, UK
    • ,
  • Judith A. Holloway

      Affiliations

    • Infection, Inflammation & Immunity, School of Medicine, University of Southampton, Southampton, UK
    • ,
  • A. Lynn Andrews

      Affiliations

    • Infection, Inflammation & Immunity, School of Medicine, University of Southampton, Southampton, UK
    • ,
  • Zeshan Riaz

      Affiliations

    • Human Genetics, School of Medicine, University of Southampton, Southampton, UK
    • ,
  • Susan J. Wilson

      Affiliations

    • Histochemistry Research Unit, School of Medicine, University of Southampton, Southampton, UK
    • ,
  • Iain A. Simpson

      Affiliations

    • Cardiothoracic Unit, Southampton General Hospital, Southampton, UK
    • ,
  • Shu Ye

      Affiliations

    • Human Genetics, School of Medicine, University of Southampton, Southampton, UK
    • Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    • Corresponding Author InformationCorresponding author at: Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK. Tel.: +44 207 882 3425; fax: +44 207 882 3408.

Received 5 August 2009 ,Revised 10 February 2010 ,Accepted 17 February 2010.

References 

  1. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241
  2. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126
  3. Duffy MJ, Lynn DJ, Lloyd AT, O'Shea CM. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb Haemost. 2003;89(4):622–631
  4. Van EP, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002;418(6896):426–430
  5. Herren B, Raines EW, Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J. 1997;11(2):173–180
  6. Lu D, Xie S, Sukkar MB, et al. Inhibition of airway smooth muscle adhesion and migration by the disintegrin domain of ADAM-15. Am J Respir Cell Mol Biol. 2007;37(4):494–500
  7. Powell RM, Wicks J, Holloway JW, Holgate ST, Davies DE. The splicing and fate of ADAM33 transcripts in primary human airways fibroblasts. Am J Respir Cell Mol Biol. 2004;31(1):13–21
  8. Richter A, Puddicombe SM, Lordan JL, et al. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol. 2001;25(3):385–391
  9. Yang Y, Haitchi HM, Cakebread J, et al. Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cells. J Allergy Clin Immunol. 2008;121(6):1393-9, 1399
  10. Ye S, Dunleavey L, Bannister W, et al. Independent effects of the −219 G>T and epsilon 2/epsilon 3/epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. Eur J Hum Genet. 2003;11(6):437–443
  11. Simpson A, Maniatis N, Jury F, et al. Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function. Am J Respir Crit Care Med. 2005;172(1):55–60
  12. Huang J, Bridges LC, White JM. Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell. 2005;16(10):4982–4991
  13. White JM. ADAMs: modulators of cell–cell and cell–matrix interactions. Curr Opin Cell Biol. 2003;15(5):598–606
  14. Gilpin BJ, Loechel F, Mattei MG, et al. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem. 1998;273(1):157–166
  15. Puxeddu I, Pang YY, Harvey A, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol. 2008;121(6):1400–1406e4
  16. Umland SP, Garlisi CG, Shah H, et al. Human ADAM33 messenger RNA expression profile and post-transcriptional regulation. Am J Respir Cell Mol Biol. 2003;29(5):571–582
  17. Zou J, Zhu F, Liu J, et al. Catalytic activity of human ADAM33. J Biol Chem. 2004;279(11):9818–9830
  18. Blakey J, Halapi E, Bjornsdottir US, et al. Contribution of ADAM33 polymorphisms to the population risk of asthma. Thorax. 2005;60(4):274–276

PII: S0021-9150(10)00164-4

doi: 10.1016/j.atherosclerosis.2010.02.023

Atherosclerosis
Volume 211, Issue 1 , Pages 224-230 , July 2010

Article Tools

* Image Usage & Resolution